7MMの視神経炎治療市場は調査期間（2020～2034年）中に大幅に成長する見込み
"Key Optic Neuritis Therapies Include Efgartigimod Alfa, OCS-05 IV Administration, Ravulizumab, B001, Inebilizumab, Divozilimab, MIL62, Satralizumab, Batoclimab, and More"
The Optic Neuritis market is anticipated to see considerable expansion over the coming years, fueled by breakthroughs in therapeutic approaches and a growing awareness surrounding the disease. The current treatment pipeline includes several high-potential drug candidates designed not only to manage acute episodes but also to reduce the risk of future relapses.
DelveInsight's report — "Optic Neuritis Market Insight, Epidemiology, and Market Forecast – 2034" — offers a thorough examination of Optic Neuritis, encompassing historical and projected epidemiological data along with market trends across the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
🔗 Unlock detailed insights into the Optic Neuritis Market by downloading the comprehensive report from DelveInsight @ Optic Neuritis Therapeutics Market
Key Highlights from the Optic Neuritis Market Report
- Market growth is expected to be largely propelled by a rising patient pool and ongoing improvements in diagnostic capabilities.
- Major players in the Optic Neuritis space include Oculis, Bio-Thera Solutions, Alexion Pharmaceuticals Inc., Amgen, Biocad, Hansoh BioMedical R&D Company, Beijing Mabworks Biotech Co., Ltd., Hoffmann-La Roche, RemeGen Co., Ltd., Chugai Pharmaceutical Co., Ltd. , HanAll Biopharma Co., Ltd. , among others.
- Notable pipeline therapies comprise Efgartigimod Alfa, OCS-05 IV Administration, Ravulizumab, B001, Inebilizumab, Divozilimab, MIL62, Satralizumab (SA237/Enspryng®), Batoclimab (HL161/HBM9161), and additional candidates.
- Research indicates that the annual incidence of Optic Neuritis in the United States is estimated at approximately 6.4 per 100,000 individuals as of 2024.
- According to the Optic Neuritis Trial Multicenter Cooperative Research Group Japan, the incidence rate in Japan was recorded at approximately 1.03 per 100,000 population in 2019.
Recent Clinical Developments (August 2024)
- Amgen initiated a Phase 2, open-label, multicenter trial evaluating the pharmacokinetics, pharmacodynamics, and safety profile of Inebilizumab in pediatric patients (ages 2 to under 18) diagnosed with active Neuromyelitis Optica Spectrum Disorder (NMOSD) who test positive for AQP4-IgG autoantibodies.
- Alexion Pharmaceuticals, Inc. launched a Phase 2/3, open-label, historically controlled, single-arm, multicenter study to assess the efficacy, pharmacokinetics, pharmacodynamics, and safety of Ravulizumab in pediatric and adolescent patients with AQP4 antibody-positive NMOSD.
- Hoffmann-La Roche commenced a Phase III, multicenter, open-label, uncontrolled study to evaluate the pharmacokinetics, efficacy, safety, tolerability, and pharmacodynamics of Satralizumab in pediatric patients with AQP4 antibody-positive NMOSD. Satralizumab, originated and developed by Chugai Pharmaceutical Co., Ltd. — a wholly owned subsidiary of Roche — functions as an anti-IL-6 receptor recycling humanized monoclonal antibody. It was first approved in Japan in 2020 for AQP4-IgG seropositive NMOSD patients and has demonstrated robust real-world effectiveness in Japanese clinical practice, with a Phase 3 pediatric study (NCT05269667) currently ongoing.
- HanAll Biopharma Co., Ltd. completed a Phase 1b/2a open-label, dose-escalation study (NCT04227470) evaluating Batoclimab (HL161/HBM9161) as add-on therapy to intravenous methylprednisolone in NMOSD patients experiencing acute attacks involving optic neuritis and/or myelitis. Batoclimab is an anti-neonatal Fc receptor (FcRn) fully human monoclonal antibody that accelerates the degradation of pathogenic AQP4-IgG autoantibodies, offering a mechanistically distinct approach from all currently approved NMOSD therapies. Results were published in the European Journal of Neurology (2023).
🔗 Gain a competitive edge in the Optic Neuritis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Optic Neuritis Treatment Drugs
Optic Neuritis Treatment Market Overview
Several key factors stand to shape the future of the Optic Neuritis Treatment Market. Continued scientific advances may yield targeted therapies that directly address the disease's root causes. Newly developed drugs and biologics could offer superior symptom management and help prevent relapses. Enhanced diagnostic technologies may enable earlier and more precise identification of the condition. Evolving long-term management protocols and healthcare policy shifts will further define treatment standards. Additionally, variability in patient outcomes and increased investment in research remain critical to driving new therapeutic discoveries and deepening the overall understanding of Optic Neuritis.
Optic Neuritis Emerging Drug Profiles
- OCS-05 – Oculis
- ST266 – Noveome Biotherapeutics
- Satralizumab (SA237 / Enspryng®) – Chugai Pharmaceutical Co., Ltd. / Hoffmann-La Roche; a recycling anti-IL-6R monoclonal antibody with Phase 3 data demonstrating a 55% relapse risk reduction in AQP4-IgG seropositive NMOSD patients, backed by approvals across Japan, US, EU, and Canada, and ongoing open-label extension and pediatric studies (NCT04660539; NCT05269667).
- Batoclimab (HL161 / HBM9161) – HanAll Biopharma Co., Ltd. (South Korea); an anti-FcRn fully human monoclonal antibody evaluated in Phase 1b/2a (NCT04227470) for acute NMOSD-related optic neuritis, demonstrating a favorable safety profile and preliminary neurological benefit as add-on to conventional steroid pulse therapy.
🔗 Discover key developments and opportunities in the Optic Neuritis Market. Click here to learn more from DelveInsight's latest report @ Optic Neuritis Market Size
Optic Neuritis Drugs and Associated Companies
- OCS-05 IV Administration – Oculis
- BAT4406F Injection – Bio-Thera Solutions
- Ravulizumab – Alexion Pharmaceuticals
- B001 – Shanghai Drug Research Development Co. Ltd.
- Inebilizumab – Hansoh BioMedical R&D Company
- Satralizumab (SA237 / Enspryng®) – Chugai Pharmaceutical Co., Ltd. , in collaboration with Hoffmann-La Roche; anti-IL-6 receptor recycling monoclonal antibody; Phase 3 completed (NCT02028884; NCT02073279); approved in Japan (2020), United States, European Union, and Canada; long-term open-label extension ongoing (NCT04660539); pediatric Phase 3 ongoing (NCT05269667).
- Batoclimab (HL161 / HBM9161) – HanAll Biopharma Co., Ltd.; anti-FcRn monoclonal antibody; Phase 1b/2a completed in NMOSD-related optic neuritis (NCT04227470); results published in European Journal of Neurology (2023); global rights (US/Canada) co-developed with Immunovant Inc.
🔗 Download DelveInsight's Optic Neuritis Market report today and stay ahead in this rapidly evolving field @ Optic Neuritis Clinical Trials
Optic Neuritis Market Dynamics
The market dynamics for Optic Neuritis are shaped by a combination of epidemiological trends, advances in diagnostic tools, evolving therapeutic pipelines, and the regulatory landscape. Sustained research efforts and continuous innovation are critical to meeting the growing need for effective treatments and improving outcomes for those living with this condition.Report Scope – Optic Neuritis Market
- Geographic Coverage: 7MM
- Key Companies: Oculis, Bio-Thera Solutions, Alexion Pharmaceuticals Inc., Amgen, Biocad, Hansoh BioMedical R&D Company, Beijing Mabworks Biotech Co., Ltd., Hoffmann-La Roche, RemeGen Co., Ltd., Chugai Pharmaceutical Co., Ltd. , HanAll Biopharma Co., Ltd. , and others
- Key Therapies: Efgartigimod Alfa, OCS-05 IV Administration, Ravulizumab, B001, Inebilizumab, Divozilimab, MIL62, Satralizumab (SA237/Enspryng®), Batoclimab (HL161/HBM9161), and others
- Competitive Intelligence: SWOT analysis and market entry strategies
- Additional Insights: Unmet needs, KOL perspectives, analyst viewpoints, market access, and reimbursement analysis
🔗 Download the report to understand which factors are driving Optic Neuritis market trends @ Optic Neuritis Market Trends
Table of Contents
- Introduction
- Optic Neuritis Executive Summary
- Optic Neuritis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II) — OCS-05: Oculis
- Early Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Inactive Products
- Companies Overview
- Product Profiles
- Unmet Needs
- Market Drivers and Barriers
- Future Perspectives and Conclusion
- Analyst Views
- Appendix
Related Reports
Optic Neuritis Epidemiology Forecast - 2034
DelveInsight’s “Optic Neuritis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of optic neuritis, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Optic Neuritis Pipeline Insight, 2026
DelveInsight’s, “Optic Neuritis- Pipeline Insight, 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Optic Neuritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The Leading Companies are Oculis , Find Therapeutics and others.
About DelveInsight
DelveInsight is a premier healthcare-focused market research and consulting firm, delivering high-caliber market intelligence and strategic analysis to support sound business decision-making. With a team of seasoned industry professionals and a strong command of the life sciences and healthcare sectors, the firm provides tailored research solutions to clients worldwide. Connect with DelveInsight to access precise, real-time insights and stay ahead in today's fast-paced healthcare landscape.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/